⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28366352 | 0.77 | — | — | |
| SCHEMBL23045665 | 0.77 | — | — | |
| Glycerylphosphate SCHEMBL59773 | 0.72 | SMPD1 (0.37) | — | |
| SCHEMBL707692 | 0.72 | SMPD1 (0.46) | — | |
| Glycerylphosphate SCHEMBL9391484 | 0.70 | SMPD1 (0.35) | — | |
| Glycerylphosphate SCHEMBL14482182 | 0.70 | SMPD1 (0.35) | — | |
| Glycerylphosphate SCHEMBL28755288 | 0.70 | SMPD1 (0.35) | — | |
| Glycerylphosphate SCHEMBL2487169 | 0.70 | SMPD1 (0.35) | — | |
| Glycerylphosphate SCHEMBL2130013 | 0.70 | SMPD1 (0.35) | — | |
| Glycerylphosphate SCHEMBL1792709 | 0.70 | SMPD1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737816-A1 | INTEGRIN MODULATORS AND METHODS FOR THEIR USE | Billings Pharmaceuticals, Inc. (US) | 2007-01-03 | — | — | EP | claimed |
| WO-2005087717-A1 | INTEGRIN MODULATORS AND METHODS FOR THEIR USE | BILLINGS PHARMACEUTICALS INC. (US) | 2005-09-22 | — | — | WO | claimed |
| EP-1003558-B1 | LIPID-POLYAMIDE CONJUGATES AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | CHIRON CORP (US) | 2004-03-17 | — | — | EP | claimed |
| US-6572881-B1 | Delivery of polynucleotides to cells; polylactam | CHIRON CORPORATION | 2003-06-03 | — | — | US | claimed |
| US-6569450-B1 | For facilitating the delivery of polynucleotides to cells | CHIRON CORPORATION | 2003-05-27 | — | — | US | claimed |
| US-6197332-B1 | ACYLATION AND AMIDATION TO FORM POLYAMIDES FOR CONJUGATED LIPIDS | CHIRON CORPORATION | 2001-03-06 | — | — | US | claimed |
| EP-0317968-B1 | Glycerides as charge directors for liquid electrostatic developers | DU PONT (US) | 1994-04-06 | — | — | EP | claimed |
| US-4886726-A | UNIFORM, HIGH QUALITY COPY IMAGES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-12-12 | — | — | US | claimed |
| EP-0317968-A2 | Glycerides as charge directors for liquid electrostatic developers | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-05-31 | — | — | EP | claimed |
| CN-114085297-A | Cyclo beta-1, 2-glucan and curcumin clathrate compound and preparation method thereof | 江南大学 | 2022-02-25 | — | — | CN | disclosed |
| US-20210198671-A1 | PROTECTED ANTIBODY-DRUG AND APTAMER-DRUG CONJUGATES | KOSAK KENNETH MICHAEL (US) | 2021-07-01 | — | — | US | disclosed |
| CN-108265090-B | Preparation method of antarctic krill oil substitute | 中粮集团有限公司 | 2021-06-15 | — | — | CN | disclosed |
| CN-106893747-B | Preparation method of PLA1 type n-3 polyunsaturated fatty acid phospholipid | 中粮集团有限公司 | 2021-03-05 | — | — | CN | disclosed |
| US-20120149940-A1 | Integrin Modulators and Methods for Their Use | BILLINGS PHARMACEUTICALS, INC. | 2012-06-14 | — | — | US | disclosed |
| EP-0317968-B1 | Glycerides as charge directors for liquid electrostatic developers | DU PONT (US) | 1994-04-06 | — | — | EP | disclosed |
| US-4981957-A | VIRICIDES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1991-01-01 | — | — | US | disclosed |
| US-4886726-A | UNIFORM, HIGH QUALITY COPY IMAGES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-12-12 | — | — | US | disclosed |
| EP-0317968-A2 | Glycerides as charge directors for liquid electrostatic developers | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-05-31 | — | — | EP | disclosed |
| EP-0169775-B1 | OLIGONUCLEOTIDES, PROCESS FOR THEIR PREPARATION AND THEIR USES AS MEDIATORS IN THE ENHANCEMENT OF THE EFFECTS OF INTERFERONS | Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1989-05-24 | — | — | EP | disclosed |
| EP-0169775-A1 | Oligonucleotides, process for their preparation and their uses as mediators in the enhancement of the effects of interferons | Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1986-01-29 | — | — | EP | disclosed |